Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism

• Management of platinum refractory ovarian cancer is challenging. • Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy. • Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option.

Detalles Bibliográficos
Autores principales: Lam, Clarissa, Ha, Kristal, Hakam, Ardeshir, Shahzad, Mian M.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079239/
https://www.ncbi.nlm.nih.gov/pubmed/35540026
http://dx.doi.org/10.1016/j.gore.2022.100992
_version_ 1784702518994927616
author Lam, Clarissa
Ha, Kristal
Hakam, Ardeshir
Shahzad, Mian M.K.
author_facet Lam, Clarissa
Ha, Kristal
Hakam, Ardeshir
Shahzad, Mian M.K.
author_sort Lam, Clarissa
collection PubMed
description • Management of platinum refractory ovarian cancer is challenging. • Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy. • Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option.
format Online
Article
Text
id pubmed-9079239
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90792392022-05-09 Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism Lam, Clarissa Ha, Kristal Hakam, Ardeshir Shahzad, Mian M.K. Gynecol Oncol Rep Case Report • Management of platinum refractory ovarian cancer is challenging. • Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy. • Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option. Elsevier 2022-05-02 /pmc/articles/PMC9079239/ /pubmed/35540026 http://dx.doi.org/10.1016/j.gore.2022.100992 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Lam, Clarissa
Ha, Kristal
Hakam, Ardeshir
Shahzad, Mian M.K.
Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
title Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
title_full Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
title_fullStr Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
title_full_unstemmed Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
title_short Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
title_sort off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079239/
https://www.ncbi.nlm.nih.gov/pubmed/35540026
http://dx.doi.org/10.1016/j.gore.2022.100992
work_keys_str_mv AT lamclarissa offlabeluseofpaclitaxelandpembrolizumabinacaseofplatinumrefractoryepithelialovariancancerandextensivethromboembolism
AT hakristal offlabeluseofpaclitaxelandpembrolizumabinacaseofplatinumrefractoryepithelialovariancancerandextensivethromboembolism
AT hakamardeshir offlabeluseofpaclitaxelandpembrolizumabinacaseofplatinumrefractoryepithelialovariancancerandextensivethromboembolism
AT shahzadmianmk offlabeluseofpaclitaxelandpembrolizumabinacaseofplatinumrefractoryepithelialovariancancerandextensivethromboembolism

Ejemplares similares